SCHEMBL5464554

SCHEMBL5464554

COc1cccc2sc(NC(=O)N3CCN(C)CC3)nc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.65
▸ NPY5R Q15761 1/20 0.59
▸ DUSP3 P51452 2/20 0.57
▸ CHRM4 P08173 1/20 0.57
▸ KDM4E B2RXH2 3/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ HPGD P15428 3/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ ADORA1 P30542 2/20 0.55
▸ TMIGD3 P0DMS9 1/20 0.55
▸ PPARG P37231 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ NR2E3 Q9Y5X4 1/20 0.55
▸ NCOR2 Q9Y618 1/20 0.55
▸ ACP1 P24666 1/20 0.54
▸ MAPT P10636 6/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16178553 0.88 DYRK1A (0.63) DYRK1ANPY5RDUSP3CHRM4KDM4E
SCHEMBL20660046 0.79 DYRK1A (0.80) DYRK1ADUSP3CHRM4KDM4ETDP1
SCHEMBL3047328 0.79 DYRK1A (0.80) DYRK1ADUSP3CHRM4KDM4ETDP1
SCHEMBL15376502 0.79 DYRK1A (1.00) DYRK1ADUSP3CHRM4KDM4ETDP1
SCHEMBL3050805 0.78 DYRK1A (0.78) DYRK1ADUSP3CHRM4KDM4ETDP1
SCHEMBL17964767 0.78 PI4KB (0.65) DYRK1ANPY5R
SCHEMBL20659925 0.77 DYRK1A (0.76) DYRK1ADUSP3CHRM4KDM4ETDP1
SCHEMBL22374141 0.76 DYRK1A (0.74) DYRK1ADUSP3CHRM4KDM4ETDP1
Hydrazine SCHEMBL20659924 0.76 DYRK1A (0.74) DYRK1ADUSP3CHRM4KDM4ETDP1
SCHEMBL9333376 0.76 DYRK1A (0.74) DYRK1ADUSP3CHRM4KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 — — US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 — — US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression HRH3, HRH1, HRH4 DYRK1A 2603/4885NPY5R 192/4885DUSP3 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback